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A B S T R A C T
Most of the newly developed drug candidates are lipophilic and poorly water-soluble. En-
hancing the dissolution and bioavailability of these drugs is a major challenge for the
pharmaceutical industry. Liquisolid technique, which is based on the conversion of the drug
in liquid state into an apparently dry, non-adherent, free flowing and compressible powder,
is a novel and advanced approach to tackle the issue.The objective of this article is to present
an overview of liquisolid technique and summarize the progress of its applications in phar-
maceutics. Low cost, simple processing and great potentials in industrial production are main
advantages of this approach. In addition to the enhancement of dissolution rate of poorly
water-soluble drugs, this technique is also a fairly new technique to effectively retard drug
release. Furthermore, liquisolid technique has been investigated as a tool to minimize the
effect of pH variation on drug release and as a promising alternative to conventional coating
for the improvement of drug photostability in solid dosage forms. Overall, liquisolid tech-
nique is a newly developed and promising tool for enhancing drug dissolution and sustaining
drug release, and its potential applications in pharmaceutics are still being broadened.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
With the advent of combinatorial chemistry and innovative
high-throughput screening, knowledge concerning physico-
chemical properties (i.e., crystal structures and salt formation)
as well as biological factors (such as metabolizing enzymes and
transporters) of drug candidates has been extensively accu-
mulated [1]. As a result, a vast number of active pharmaceutical
ingredients have been produced. However, most of these drugs
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are very lipophilic and poorly water-soluble [2]. It is reported
that about 40% of the newly developed drugs and nearly 60%
of the synthesized chemical entities suffer from solubility issues
[3,4]. Therefore, to enhance the solubility and dissolution of
these poorly water-soluble drugs and improve their
bioavailabilities are a matter of concern for many pharma-
ceutical scientists.The bioavailability of these Biopharmaceutical
Classification System Class II (BCS II) drugs is often limited by
their solubility and dissolution rate in the gastrointestinal tract
[5,6].
Many suitable formulation approaches have been devel-
oped to increase the solubility of poorly water-soluble drugs.
Micronization technique is the most commonly used ap-
proach to improve drug solubility due to an increase in surface
area, but the agglomeration tendency of micronized hydro-
phobic drugs makes it less effective to circumvent the solubility
problem, especially when the drug is formulated into tablets
or encapsulations [7]. Solid dispersion has gained an active re-
search interest for improving drug dissolution in the past few
decades, however its commercial application is very limited
and only a few products, such as Kaletra® and Gris-PEG® have
become commercially available. The reason mainly lies on its
poor stability during storage and lack of understanding of its
solid-state structure [8]. Formulating soft gelatin capsules is
another widely used approach, whereas it is costly and re-
quires sophisticated technologies [9]. Other approaches, such
as inclusion complexation [10], microencapsulation [11], and
preparation of nanosuspensions [12], self-nanoemulsions [13]
and solid lipid nanoparticles [14] have also been studied for
dissolution enhancement of poorly water-soluble drugs. But
these approaches involve high production cost and entail ad-
vanced preparation method and/or sophisticated machinery.
Liquisolid technique, a newly developed and advanced
method for dissolution enhancement, can overcome many
aforementioned barriers [15–17]. This technique was first in-
troduced by Spireas et al. and applied to incorporate water-
insoluble drugs into rapid release solid dosage forms.The design
principle of liquisolid system is to contain liquid medica-
tions (i.e., liquid drugs, drug solutions or suspensions) in
powdered form and delivery drug in a similar way to soft gelatin
capsules containing liquids. Liquisolid technique refers to the
conversion of liquid medications into apparently dry,
non-adherent, free flowing and compressible powder mix-
tures by blending the liquid medications with suitable
excipients, which are generally termed as carriers and coating
materials [18,19]. The liquid medication is first absorbed into
the interior framework of the carrier. Once the interior of the
carrier is saturated with liquid medication, a liquid layer is
formed on the surface of carrier particles, which is instantly
adsorbed by the fine coating materials. Consequently, an ap-
parently dry and free flowing and compressible powder mixture
is formed. The mechanism of liquisolid system formation is
displayed in Fig. 1. Usually, orally safe, and preferable water-
miscible organic solvents with high boiling point, such as
propylene glycol and polyethylene glycol (PEG) 400, are used
as the liquid vehicles. Carriers refer to porous materials with
large specific surface area and high liquid absorption capac-
ity to absorb liquid medication [19].Various grades of cellulose,
starch and lactose can be adopted as carriers. However, only
excipients with very fine particle size and highly adsorptive
property, such as silica powder, can be used as coating mate-
rials [21].
Even though the drug within liquisolid system is in a solid
state, it exists exactly in a completely or partly molecularly dis-
persed state [22,23]. Therefore, a liquisolid system may exhibit
enhanced dissolution rate due to the increased dissolution area,
enhanced aqueous solubility, or improved wetting properties
[24]. Apart from dissolution enhancement, liquisolid tech-
nique has recently been investigated as a tool to retard drug
release [25–27], to minimize the influence of pH variation on
dissolution profile [28,29], and to improve drug photostability
[30]. Finally, it is worth mentioning that liquisolid systems are
not associated with stability issues [15,31–33].This article pres-
ents an overview of the liquisolid technique and the advance
in its applications in pharmaceutics.
2. Theory of liquisolid system
A powder can only retain limited amount of liquidmedication
while maintaining acceptable flowability and compressibility.
Therefore, in order to attain a liquisolid system with accept-
ableflowable andcompressibleproperties,amathematicalmodel
Liquids
(Liquid drug, drug solution, 
drug suspension)
Carrier particles
Incorporation of liquids
Carrier saturated with liquids
A liquid layer formed on 
particle surface
Addition of coating particles
Conversion from a wet to 
a dry surface
Fig. 1 – Mechanism of liquisolid system formation. Figure adapted from Reference [20].
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introduced and validated by Spireas is recommended to cal-
culate the appropriate quantities of carrier and coatingmaterial
[18–20]. The model is based on two fundamental properties of
a powder, i.e., flowable liquid retention potential ( Φ value) and
compressible liquid retention potential ( Ψ value). The Φ and
Ψ values of a powder excipient represent themaximumquan-
tity of liquid vehicle that can be retained in the powder bulk
without compromising flowability and compressibility [19].The
Φ value is preferably determined by measuring the angle of
slide of the prepared liquid–powder admixture.And the Ψ value
can be measured by an experiment called pactisity, which is
defined as the maximum crushing strength of a tablet with a
tablet weight of one gramwhen compressed at sufficient com-
pression force [19,21].
The excipients ratio ( R), which is also known as the carrier/
coating ratio, is defined as follows:
R = Q q (1)
Therefore, R is the ratio between the weights of carrier
(Q ) and coating material ( q). An increase in the R value will
lead to higher quantities of the carrier and lower amounts of
the coating material. As the R value is associated with the
flowability and compressibility properties, disintegration, and
dissolution rate of the liquisolid system, an optimum value of
R is recommended to be 20 [21,34]. Another important pa-
rameter of the liquisolid system is termed as liquid loading
factor ( Lf ), which is defined as the weight ratio of the liquid
medication (W ) and the carrier material (Q ) in the liquisolid
system.
L W Qf = (2)
The liquid loading factor for the production of a liquisolid
system with acceptable flowability can be determined by:
Φ ΦLf = + ϕ R (3)
Where Φ and ϕ values correspond to the flowable liquid
retention potential of the carrier and coating material, respec-
tively. Correspondingly, the liquid loading factor to ensure
acceptable compressibility of a liquisolid system can be de-
termined by:
Ψ ΨLf = + ψ R (4)
Where Ψ and ψ values correspond to the compressible
liquid retention potential of the carrier and coating material,
respectively. Therefore, the optimum liquid loading factor ( L0 )
that produces a liquisolid system with acceptable flowability
and compressibility is equal to either ΦLf or ΨLf , whichever
has the lower value.
As Φ, Ψ, ϕ , and ψ values are constants for each powder–
liquid combination, for a given excipients ratio ( R), the optimum
liquid loading factor ( L0 ) can be calculated according to Equa-
tions (3) or (4).Then, according to different drug concentrations,
different weights of liquid medication (W ) will be used.Thus,
based on the calculated L0 and W , the appropriate amount
of carrier (Qo ) and coating material ( qo ) can be calculated ac-
cording to Equations (1) and (2), respectively.
3. Advantages and disadvantages of
liquisolid technique
3.1. Advantages [16,30,35,36]
Numerous advantages of liquisolid technique have been re-
ported. (i) Huge number of slightly water-soluble, very slightly
water-soluble and practically water-insoluble drugs can be for-
mulated into liquisolid systems with enhanced dissolution and
bioavailability. (ii) Sustained release formulations with zero order
release pattern can be achieved provided that hydrophobic car-
riers, such as Eudragit® RL and RS, or retarding agents such as
hydroxypropyl methylcellulose (HPMC) are used in the liquisolid
systems. (iii) This technique has the potential to produce
liquisolid tablets or capsules with pH-independent drug release
profiles. (iv) It is a promising alternative to conventional coating
approach for the improvement of drug photostability in solid
dosage forms. (v) The applied excipients are easily available
and cost-effective. Besides, the preparation process is simple,
which is similar to conventional solid dosage forms (i.e. tablets
and capsules). Moreover, the good flowability and compress-
ibility of liquisolid powdermake the technique feasible for large-
scale production.
3.2. Disadvantages [37,38]
There are also disadvantages associated with liquisolid tech-
nique. (i) The technique is successfully applied for low dose
water-insoluble drugs, whereas the incorporation of high dose
water-insoluble drugs into liquisolid systems is its main limi-
tation. As these drugs require large quantity of liquid vehicle,
therefore, in order to obtain liquisolid powder with good flow
and compressible properties, large amounts of carrier and
coating material are required.This may increase tablet weight
over the limit, which is difficult for patients to swallow. Several
strategies have been reported to address the above obstacle.
For example, adding some additives (i.e., PVP and PEG 35000)
into the liquid medications to increase the viscosity can reduce
the quantities of carrier and coating material. Additionally, ap-
plication of modern carrier and coating materials (such as
Fujicalin® and Neusilin®) with large specific surface area (SSA)
and high absorption capacity is another efficient way to load
high dose water-insoluble drugs. (ii) A high solubility of drug
in liquid vehicle is required to prepare liquid solid systems.
4. Formulation design and preparation of
liquisolid system
4.1. Formulation design of liquisolid system
4.1.1. Liquid vehicle
Liquid vehicle used in liquisolid systems should be orally safe,
inert, not highly viscous, and preferably water-miscible non-
volatile organic solvents, such as propylene glycol, glycerin, PEG
200 and 400, polysorbate 20 and 80, etc [39]. The solubility of
drug in nonvolatile solvent has an important effect on tablet
weight and dissolution profile. Higher drug solubility in the
solvent leads to lower quantities of carrier and coating
117a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 1 1 5 – 1 2 3
material, and thus lower tablet weight can be achieved. On the
other hand, the higher the drug solubility in the solvent, the
greater FM value (the fraction of molecularly dispersed drug)
will be, which confers an enhancement of the dissolution rate
[16,40]. The selection of liquid vehicle mainly depends on the
aim of study. Namely, a liquid vehicle with high ability to solu-
bilize drug will be selected in the case of dissolution
enhancement.While if the aim is to prolong drug release, liquid
vehicle with the lowest capacity for solubilizing drug may be
chosen [27]. In addition to the drug solubility in liquid vehicle,
several other physicochemical parameters such as the polar-
ity, lipophilicity, viscosity, and chemical structure also have
significant effects on drug release profiles [21].
Moreover, it is claimed that liquid vehicle can act as a binder
in a low concentration, which contributes to the compact-
ness of liquisolid tablets. The reason may lie on the presence
of hydroxyl groups in the molecular structure of liquid vehicle
which leads to hydrogen bonding between solvents and other
excipients in liquisolid formulations [41].
4.1.2. Carriers
Carriers should possess porous surface and high liquid ab-
sorption capacity [18].As carriers allow an incorporation of large
amount of liquid medication into the liquisolid structure, the
properties of carriers, such as (SSA) and liquid absorption ca-
pacity, are of great importance in designing the formulation
of liquisolid system. The liquid adsorption capacity mainly
depends on the SSA value. Additionally, it is also influenced
by the type of coating material and the physicochemical prop-
erties of the liquid vehicle, such as polarity, viscosity, and
chemical structure [42].
Currently, microcrystalline cellulose (MCC) with SSA of
1.18 m2/g is the most commonly used carrier. Javadzadeh [15]
investigated the effect of three grades of MCC (i.e., PH 101, 102,
and 200) on the flowability and compressibility as well as the
dissolution rate of piroxicam liquisolid tablets. It was ob-
served that liquisolid formulations prepared from MCC PH 101
exhibited better flowability, compressibility, and dissolution pro-
files compared with those prepared from MCC PH102 and 200.
In addition, aging has no significant effect on the hardness and
dissolution profiles of the prepared liquisolid tablets. Overall,
MCC PH 101 is a suitable carrier to prepare liquisolid systems
in terms of flowability, compressibility, and dissolution profile.
Apart from MCC, other general carriers, such as lactose (SSA
0.35 m2/g), sorbitol (SSA 0.37 m2/g), and starch (SSA – 0.6 m2/
g) have relatively limited applications due to their low SSA
values [43]. As a result of the low SSA value of carriers, large
amounts of carriers are required for the conversion of liquid
medication into apparently dry, free flowing and compress-
ible powder mixture, which will further lead to the increase
in tablet weight. In addition to these carriers, Eudragit® RL and
RS are also commonly used in the preparation of liquisolid
systems with sustained drug release patterns [25].
Recently, several promising carriers with extremely high SSA
value and greater liquid absorption capacity are available at
the market. For instance, Fujicalin®, a synthetic anhydrous
dibasic calcium phosphate, has a SSA value of 40 m2/g and a
liquid absorption ability up to 1.2 ml/g [44]. Hentzschel et al.
[42] prepared tocopherol acetate liquisolid system using
Fujicalin® as a carrier. Their results further confirmed that
Fujicalin® is a suitable carrier for preparing liquisolid systems.
In addition, Neusilin®, another newly-developed carrier, is an
amorphous form of magnesium aluminometasilicate with a
SSA value up to 300 m2/g. Neusilin® is commercially available
in eleven grades, among which Neusilin® US2 (SSA of 300 m2/
g, liquid adsorption capacity up to 3.4 mL/g) is the most
commonly used carrier [45]. Vranikova et al. [46] determined
the flowable liquid retention potential of Neusilin® US2 for three
different nonvolatile solvents, it was observed that 1 gram of
Neusilin® US2 could retain up to 1 gram of propylene glycol,
1.16 gram of PEG 400 and 1.48 gram of PEG 200 while main-
taining acceptable flowability. Therefore, the large SSA value
and high absorption capacity makes Neusilin® US2 an excel-
lent carrier for liquisolid systems. Hentzschel et al. [47] adopted
Neusilin® US2 as a carrier to prepare griseofulvin liquisolid
system in comparison with Avicel®. The results showed that
Neusilin® possessed seven-fold higher liquid adsorption ca-
pacity than Avicel®, which allowed a production of liquisolid
tablets with lower tablet weights. Furthermore, apart from
Fujicalin® and Neusilin®, orderedmesoporous silicates own even
larger specific surface (up to 1500 m2/g [48]) and larger pore
volume, which enables it to be a promising choice in design-
ing liquisolid formulations. Chen et al. [49] prepared
carbamazepine using ordered mesoporous silicates as a carrier.
It was clear that ordered mesoporous silicates formed good res-
ervoirs for liquid medication and showed a substantial increase
in drug loading capacity.
4.1.3. Coating materials
Coating materials refer to very fine and highly adsorptive ma-
terials, such as Aerosil® 200, Neusilin®, and calcium silicate or
magnesium aluminometasilicates in a powder form.These ma-
terials play a contributory role in covering the wet carrier
particles to form an apparently dry, non-adherent, and free
flowing powder by adsorbing any excess liquid [50]. It was
proved that the replacement of Aerosil® 200 by Neusilin® US2
as a coating material in liquisolid system considerably in-
creased the liquid adsorption capacity and reduced tablet weight
[47]. Since Neusilin® can be either a carrier or a coating ma-
terial, its usage will greatly simplify the preparation procedure
of liquisolid formulations [47].
4.1.4. Additives
The disintegration of solid dosage forms obviously influ-
ences drug release.Therefore, disintegrants are usually included
in liquisolid tablets to allow a fast disintegration. Some com-
monly used disintegrants in liquisolid system include sodium
starch glycolate, croscarmellose sodium, and low substituted
hydroxypropyl cellulose [51]. Polyvinylpyrrolidone (PVP) is
another promising additive, which has the potential to incor-
porate high amount of drug into liquisolid systems, and thus
reduce the tablet weight [38]. Besides, due to the crystal growth
inhibition effect of PVP, liquisolid tablets containing PVP show
an improvement of dissolution rate [37]. There is another ad-
ditive in liquisolid systems – HPMC, which usually acts as a
release retarding agent to extend drug release [36].
4.2. General preparation procedures of liquisolid system
Calculated amounts of drug and liquid vehicle are mixed, and
then heated or sonicated for completely solubilizing or evenly
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blending. The following mixing process of the resulted liquid
medication with other excipients used in the liquisolid for-
mulation is carried out in three steps as described by Spireas
and Bolton [18]. During the first stage, the resulted liquid medi-
cation is poured onto calculated quantity of carrier material
and blended at an approximate mixing rate of one rotation per
second for one minute to facilitate a homogenous distribu-
tion of liquid medication throughout the carrier powder.Then,
coating material in calculated amount is added and mixed
homogenously. In the second stage, the prepared powder
mixture is spread as a uniform layer on the surface of a mortar
and left standing for 5 min to facilitate a complete absorp-
tion of drug medication into the interior framework of carrier
and coating materials. In the third stage, disintegrant is added
and mixed thoroughly with the above powder mixture, and a
final liquisolid system is obtained. The prepared liquisolid
system can be further compressed or encapsulated. It has to
be mentioned that the mixing speed, mixing time, and stand-
ing time can be adapted according to specific case. The
preparation procedures of liquisolid system are displayed in
Fig. 2.
5. Applications of liquisolid technique in
pharmaceutics
5.1. Liquisolid technique as a tool to enhance drug
dissolution
Based on the literatures, liquisolid technique has been widely
used to improve the dissolution rate of low dose insoluble drugs,
such as prednisolone [21], famotidine [22], valsartan [53],
ketoprofen [54], raloxifene hydrochloride [23], clonazepam [24],
clofibrate [55], etc. In the case of high dose water insoluble drugs
(i.e., carbamazepine), the feasibility of liquisolid technique has
also been discussed. Javadzadeh et al. suggested [38] that it is
possible to involve liquisolid technique in the incorporation
of high dose water-insoluble drugs into liquisolid systems by
adding some additives (such as PVP, HPMC and polyethylene
glycol 35000), because these additives have the capability to
increase the liquid absorption capacity of carrier and coating
materials. Hentzschel et al. [42] have shown another poten-
tial approach to load high dose of poorly water-soluble drugs
into liquisolid systems, namely by using modern carriers (such
as Neusilin®) with larger SSA value and higher absorption
capacity.
Recently, Pezzini et al. [56] explored the possibility of using
this technique to prepare liquisolid pellets for dissolution en-
hancement of felodipine. It was observed that a liquisolid
microenvironment with soft structures and high porosity was
formed, which favored the disintegration and dissolution
process of felodipine liquisolid pellets. The results indicated
that it is feasible to adopt liquisolid pellets as novel drug de-
livery systems to improve the dissolution rate of poorly water-
soluble drugs.A comparative study to corroborate the feasibility
of liquisolid technique is performed by Khan et al. [57], in which
the liquisolid technique was applied to enhance the dissolu-
tion rate of hydrochlorothiazide in comparison with solid
dispersion technique. The obtained results showed liquisolid
systems enhanced the drug dissolution rate to 95%while it only
increased to 88% for solid dispersions.Thus a conclusion could
be drawn that the liquisolid technique was more effective than
solid dispersion technique in improving the rate and extent
of drug release.
Furthermore, the in vivo profiles of liquisolid tablets have
been studied by several researchers. For example, Khaled et al.
[58] evaluated the in vivo performance of hydrochlorothiazide
liquisolid tablets in six male Beagle dogs using two-way cross-
over design. It was shown that hydrochlorothiazide liquisolid
tablets exhibited 15% greater bioavailability than the commer-
cial oral dosage form. Recently, in another study, the clinical
evaluation of mosapride citrate liquisolid tablets was per-
formed by Badawy et al. [29] in six healthymale volunteers aged
twenty to forty years.A randomized, single dose, two-way cross-
over open-label design was used for the study. The authors
+
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Solid drugs Drug in solution 
or suspension
Liquid drugsor
Liquid medication
Wet particles
Coating material
Liquisolid system
Final formulation
Tabletting or encapsulation
Carrier material
Addition of other 
excipients
Fig. 2 – Preparation procedures of liquisolid system. Figure adapted from Reference [52].
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concluded that mosapride citrate liquisolid tablets could in-
crease the oral bioavailability when compared with the
commercial counterparts, with significantly improved phar-
macokinetic parameters (i.e., Cmax, Tmax, and AUC(0–12)).
Three possible mechanisms of dissolution enhancement for
liquisolid systems have been proposed in the literature, namely
increased drug surface area, increased drug solubility, and in-
creased wetting properties. Even though the drug is held in a
solid dosage form, it is presented either in a solubilized or dis-
persed state. Therefore, the drug surface area available for
dissolution is markedly increased [16,17,22]. In addition to the
preceding mechanism, the drug solubility could be increased
in the aqueous diffusion layer. It is recognized that the rela-
tively small amount of liquid vehicle existed in the liquisolid
system may be insufficient to increase the overall drug
solubility in the dissolution medium. However, in the microen-
vironment of diffusion layer between the individual liquisolid
primary particle and the dissolution medium, liquid vehicle
may act as a co-solvent and diffuses out of the primary par-
ticle together with the drug, which might be adequate to
increase drug solubility [22,59,60]. Moreover, due to the surface
activity of liquid vehicles, the interfacial tension between tablet
surface and dissolution media can be reduced, which leads to
an improved wettability of the hydrophobic drug [31,60]. Re-
cently, we have improved the dissolution of tadalafil, a poorly
water-soluble drug, by employing the liquisolid technique.Mean-
while, the mechanism of enhanced dissolution was also
investigated.The results suggested that a reduction of the par-
ticle size and crystallinity and an enhancement of the
wettability were the main mechanisms for the enhanced dis-
solution rate of tadalafil [61].
5.2. Liquisolid technique as a tool to sustain drug release
Liquisolid technique is initially designed to enhance the dis-
solution rate of poorly water-soluble drugs. In the past few years,
extensive studies indicated that the liquisolid technique could
be utilized as a promising method for preparing sustained
release formulations of different drugs [25,26,52,62]. Sus-
tained release formulations are designed to release the drug
slowly at a predetermined rate for a certain period of time with
high efficacy, high patient compliance, and minimum side
effects. One of the main advantages of applying liquisolid tech-
nique in prolonging drug release is the possibility to attain a
liquisolid system with zero order release kinetics [25–27].
However, its main limitation lies on the high tablet weight,
which is attributed to the high dose of drug used in the sus-
tained release liquisolid formulations (usually higher than that
in conventional tablets) [43].The principle behind liquisolid tech-
nique to sustain drug release is mainly based on the hypothesis
that by involving hydrophobic carriers (i.e. Eudragit® RL and
RS) instead of hydrophilic carrier or retarding agents (such as
HPMC) in the liquisolid formulations, a prolonged drug release
pattern can be achieved [25,63]. Besides, as the SSA value of
the commonly used hydrophobic carriers (such as Eudragit®
RL and RS) are usually lower than that of the hydrophilic car-
riers such as MCC, the amount of coating material (such as
silica, a hydrophobic material) that required to convert wetting
carrier particles to apparently dry and free flowing powders
will be generally higher [25]. This may aid in sustaining drug
release.Moreover, it was claimed that by selecting suitable types
of liquisolid vehicle, a prolonged drug release pattern could also
be obtained [62].
Many attempts have been made to optimize the sus-
tained release liquisolid formulations. Javadzadeh et al. [25]
investigated the feasibility of this technique to prolong the
release of propranolol hydrochloride. The results showed that
liquisolid technique can be adopted as a new tool to prepare
sustained release matrices with zero-order release kinetic.The
authors pointed out that polysorbate 80 (Tween 80) had an im-
portant role in sustaining drug release. Due to the plasticizer
effect of Tween 80, the glass transition temperature (Tg) of
polymer that applied in the formulation could be reduced. As
a result, the polymer chains would coalesce better, which re-
sulted in a fine polymer network with lower porosity and higher
tortuosity. During the release process, drug was surrounded and
restricted by the fine network, and thus prolonged the drug
release. In another innovative study, Nokhodchi et al. [26] evalu-
ated the effect of co-solvent and HPMC on theophylline release.
It was concluded that the presence of non-volatile co-solvent
was critical for prolonging drug release.The sustained release
action of HPMC was amplified and desirable release profile was
achieved by changing the type of co-solvent. Similar conclu-
sions were made by Khanfar et al. [64] where venlafaxine
hydrochloride liquisolid tablets exhibited greater retardation
effect compared with the directly compressed tablets.The type
of liquid vehicle was observed to affect drug release signifi-
cantly. Other important factors included drug concentration
in the liquid medication and excipients ratio ( R). Specifically,
drug release from liquisolid tablets could be decreased with
the increase of drug concentration. A reduction of drug release
was observed in liquisolid tablets with higher R value.This was
because the amount of carrier and swelling agents (HPMC) was
increased in these formulations, which led to a slow diffu-
sion of drug through the porous carrier and the gel layer formed
by HPMC.The authors further concluded that prolonged drug
release profiles over a period of twelve hours were obtained
from liquisolid tablets containing Tween 80 as a liquid vehicle,
Avicel® as a carrier, and HPMC as a retarding agent. Adibkia
et al. [52] claimed that the solubility of drug in liquid vehicle
had a significant effect on drug release profiles. Additionally,
other physicochemical properties such as the formation of mi-
celles, dielectric constant and HLB also affect drug release
profiles.
5.3. Liquisolid technique as a tool to minimize the
influence of pH variation on drug release
The solubility of weak acids and bases is dependent on the ion-
ization constant (pKa) of the compound and pH of the local
environment. Therefore, the dissolution and bioavailability of
these drugs are greatly influenced by the pH of gastrointesti-
nal fluids.This further leads to a high degree of inter- and intra-
variability in drug bioavailability and therapeutic effects [29,65].
El-Hammadi et al. [28] first explored the possibility of using
liquisolid technique to minimize the influence of pH varia-
tion on the release of loratadine. Several liquisolid formulations
were prepared using propylene glycol as a liquid vehicle, MCC
as a carrier, and silica as a coating material. The dissolution
profile of the prepared liquisolid tablets was investigated in
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three buffered media with pH values of 1.2, 2.5, and 5, respec-
tively. The results indicated that the dissolution rates of
liquisolid tablets were significantly higher and less affected by
pH variation in comparison with the directly compressed tablets
and marketed tablets (Clarityn®). The results suggested that
liquisolid technique is a promising tool to minimize the in-
fluence of pH variation on the dissolution rate of poorly water-
soluble drugs. Similar results were also reported by Chella et al.
[33] where an optimized liquisolid formulation was obtained
with a significant improvement in dissolution and a less pH-
dependent release profile compared to drug alone or its
commercial formulation. In another study, Badawy et al. [29]
demonstrated the robustness of mosapride citrate (a poorly
soluble weak base) liquisolid tablets, which minimize the effect
of pH variation on drug release along the gastrointestinal tract
with bio-relevant media.
5.4. Liquisolid technique as a promising tool to improve
drug photostability in solid dosage forms
A loss of drug potency during the photodegradation process
may result in toxic degradation products and causing poten-
tial side effects, thus the photostability study is an indispensable
part of pre-formulation studies for photosensitive drugs [30,66].
The principle behind photoprotective action of liquisolid tech-
nique is based on the photoprotective property of silicon dioxide
(a commonly used coating material in liquisolid system) due
to its high refractive index and the capability to diffract light
waves of different energies [30].
Khames [30] designed a study to evaluate the possibility of
using liquisolid technique as a promising alternative to con-
ventional coating for the improvement of drug photostability.
Several liquisolid formulations of amlodipine (a photosensi-
tive drug) were prepared, where Avicel® PH 102 was used as
the carrier, nanometer-sized amorphous silicon and tita-
nium dioxide either alone or in combination was used as the
coating material. The prepared amlodipine liquisolid formu-
lations were irradiated with visible light, UVA and UVB with
different light dose for eight hours. Meanwhile, the conven-
tional film coating tablets and drug alone were tested in the
same way for comparison. It was found that all liquisolid for-
mulations showed significant photoprotective effect with a
residual drug percentage of 97.37% compared to 73.8% for the
drug alone after eight hours of irradiation (P < 0.05). Besides,
the photoprotective action of liquisolid tablets was compa-
rable to the conventional film coating tablets (titanium dioxide
as the sunscreen, P > 0.05). To be specific, the photoprotective
effect of liquisolid tablets was inversely proportional to the ex-
cipients ratio ( R). As a conclusion, liquisolid technique was
proved to be a promising alternative to conventional coating
for improving drug photostability in solid dosage forms.
6. Conclusion
To enhance the solubility and dissolution of poorly water-
soluble drugs is still a matter of concern for pharmaceutical
scientists. A review of extensive literatures indicates that the
development of liquisolid technique is advancing very fast in
the past few years. Liquisolid technique is not only a useful
tool to improve the dissolution rate of poorly water-soluble
drugs, but also an innovative and excellent method to prepare
sustained release tablets with zero order release pattern. More-
over, the technique has exhibited great potential in reducing
the effect of pH variation on drug release and improving drug
photostability in solid dosage forms. Other potential applica-
tions of this technique in pharmaceutics are to be explored in
the future. Further studies regarding the development of ex-
cellent solvents as well as modern carrier and coating materials
for loading high dose drugs are still underway. Currently, much
research work still focuses on the formulation development
of liquisolid systems and the investigation of in vitro drug release
profiles. Future works on themeasurement of loading high dose
water-insoluble drugs, and in vivo evaluation of liquisolid
systems need to be explored and strengthened.
R E F E R E N C E S
[1] Lipinski CA, Lombardo F, Dominy BW, et al. Experimental
and computational approaches to estimate solubility and
permeability in drug discovery and development settings.
Adv Drug Deliv Rev 2001;46:3–26.
[2] Stegemann S, Leveiller F, Franchi D, et al. When poor
solubility becomes an issue: from early stage to proof of
concept. Eur J Pharm Sci 2007;31:249–261.
[3] Liversidge EM. Nanocrystals: resolving pharmaceutical
formulation issues associated with poorly water soluble
compounds. In: Marty JJ, editor. Particles. Orlando: Marcel
Dekker; 2002.
[4] Giliyar C, Fikstad DT, Tyavanagimatt S. Challenges and
opportunities in oral delivery of poorly water-soluble drugs.
Drug Del Technol 2006;6:57–63.
[5] Amidon GL, Lennernas H, Crison JR, et al. A theoretical basis
for a biopharmaceutic drug classification: the correlation of
in vitro drug product dissolution and in vivo bioavailability.
Pharm Res 1999;12:413–420.
[6] Yadav AV, Shete AS, Dabke AP. Formulation and evaluation
of orodispersible liquisolid compacts of aceclofenac. Indian J
Pharm Educ 2010;44:227–235.
[7] Aguiar AJ, Zelmer AJ, Kinkel AW. Deaggregation behavior of
a relatively insoluble substituted benzoic acid and its
sodium salt. J Pharm Sci 1979;56:1243–1252.
[8] Craig DQM. The mechanisms of drug release from solid
dispersions in water-soluble polymers. Int J Pharm
2002;231:131–144.
[9] Ebert WR. Soft gelatin capsules: unique dosage form. Pharm
Tech 1977;1:44–50.
[10] Hiremath SN, Raghavendra RK, Sunil F, et al. Dissolution
enhancement of gliclazide by preparation of inclusion
complexes with β-cyclodextrin. Asian J Pharm 2008;2:73–76.
[11] Li DX, Oh YK, Lim SJ, et al. Novel gelatin microcapsule with
bioavailability enhancement of ibuprofen using spray-drying
technique. Int J Pharm 2008;355:277–284.
[12] Kocbek P, Baumgartner S, Kristl J. Preparation and
evaluation of nanosuspensions for enhancing the
dissolution of poorly soluble drugs. Int J Pharm
2006;312:179–186.
[13] Mahmoud EB, Nazrul H, Gihan F, et al. Solubility and
dissolution enhancement of tadalafil using self-
nanoemulsifying drug delivery system. J Oleo Sci
2014;63:567–576.
[14] Müller RH, Runge S, Ravelli V, et al. Oral bioavailability of
cyclosporine: solid lipid nanoparticles (SLN®) versus drug
nanocrystals. Int J Pharm 2006;317:82–89.
121a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 1 1 5 – 1 2 3
[15] Javadzadeh Y, Shariati H, Movahhed-Danesh E, et al. Effect
of some commercial grades of microcrystalline cellulose on
flowability, compressibility, and dissolution profile of
piroxicam liquisolid compacts. Drug Dev Ind Pharm
2009;35:243–251.
[16] Elkordy AA, Tan XN, Essa EA. Spironolactone release from
liquisolid formulations prepared with Capryol™ 90, Solutol®
HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles.
Eur J Pharm Biopharm 2013;83:203–223.
[17] Suliman AS, Anderson RJ, Elkordy AA. Norfloxacin as a
model hydrophobic drug with unique release from liquisolid
formulations prepared with PEG 200 and Synperonic PE/L-61
non-volatile liquid vehicles. Powder Technol 2014;257:156–
167.
[18] Spireas S, Bolton SM. Liquisolid systems and methods of
preparing same. US5968550, 1999.
[19] Spireas S. Liquisolid system and method of preparing same.
U.S Patent 6423339B1, 2002.
[20] Spireas SS, Jarowski CI, Rohera BD. Powdered solution
technology: principles and mechanism. Pharm Res
1992;9:1351–1358.
[21] Spireas S, Sadu S. Enhancement of prednisolone dissolution
properties using liquisolid compacts. Int J Pharm
1998;166:177–188.
[22] Fahmy RH, Kassem MA. Enhancement of famotidine
dissolution rate through liquisolid tablets formulation: in
vitro and in vivo evaluation. Eur J Pharm Biopharm
2008;69:993–1003.
[23] Komala DR, Janga KY, Jukanti R, et al. Competence of
raloxifene hydrochloride loaded liquisolid compacts for
improved dissolution and intestinal permeation. J Drug
Deliv Sci Technol 2015;30:232–241.
[24] Sanka K, Poienti S, Mohd AB, et al. Improved oral delivery of
clonazepam through liquisolid powder compact
formulations: in-vitro and ex-vivo characterization. Powder
Technol 2014;256:336–344.
[25] Javadzadeh Y, Musaalrezaei L, Nokhodchi A. Liquisolid
technique as a new approach to sustain propranolol
hydrochloride release from tablet matrices. Int J Pharm
2008;362:102–108.
[26] Nokhodchi A, Aliakbar R, Desai S, et al. Liquisolid compacts:
the effect of cosolvent and HPMC on theophylline release.
Colloids Surf B Biointerfaces 2010;79:262–269.
[27] Pavani E, Noman S, Syed IA. Liquisolid technique based
sustained release tablet of trimetazidine dihydrochloride.
Drug Invention Today 2013;5:302–310.
[28] El-Hammadi M, Awad N. Investigating the use of liquisolid
compacts technique to minimize the influence of pH
variations on loratadine release. AAPS PharmSciTech
2012;13:53–58.
[29] Badawy MA, Kamel AO, Sammour OA. Use of biorelevant
media for assessment of a poorly soluble weakly basic drug
in the form of liquisolid compacts: in vitro and in vivo study.
Drug Deliv 2016;23:818–827.
[30] Khames A. Liquisolid technique: a promising alternative to
conventional coating for improve ment of drug
photostability in solid dosage forms. Drug Deliv
2013;10:1335–1343.
[31] Javadzadeh Y, Siahi MR, Asnaashari S, et al. An investigation
of physicochemical properties of piroxicam liquisolid
compacts. Pharm Dev Technol 2007;12:337–343.
[32] Javadzadeh Y, Siahi MR, Asnaashari S, et al. Liquisolid
technique as a tool for enhancement of poorly water-soluble
drugs and evaluation of their physicochemical properties.
Acta Pharm 2007;57:99–109.
[33] Chella N, Narra N, Rama RT. Preparation and
characterization of liquisolid compacts for improved
dissolution of telmisartan. J Drug Deliv 2014;2014:1–10.
[34] Tayel SA, Soliman II, Louis D. Improvement of dissolution
properties of carbamazepine through application of the
liquisolid tablet technique. Eur J Pharm Biopharm
2008;69:342–347.
[35] Gubbi SR, Jarag R. Formulation and characterization of
atorvastatin calcium liquisolid compacts. Asian J Pharm Sci
2010;5:50–60.
[36] Karmarkar AB, Gonjari ID, Hosmani AH, et al. Evaluation of
in vitro dissolution profile comparison methods of sustained
release tramadol hydrochloride liquisolid compact
formulations with marketed sustained release tablets. Drug
Discov Ther 2010;4:26–32.
[37] Singh SK, Srinivasan KK, Gowthamarajan K, et al. Influence
of formulation parameters on dissolution rate enhancement
of glyburide using liquisolid technique. Drug Dev Ind Pharm
2012;38:961–970.
[38] Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A, et al.
Liquisolid technique for dissolution rate enhancement of a
high dose water-insoluble drug (carbamazepine). Int J Pharm
2007;341:26–34.
[39] Charman SA, Charman WN. Oral modified release delivery
systems. In: Rathbone MJ, Hadgraftb J, Roberts MS, editors.
Modified release drug delivery technology. NewYork: 2003. p.
1–9.
[40] Saeedi M, Akbari J, Morteza-Semnani K, et al. Enhancement
of dissolution rate of indomethacin using liquisolid
compacts. Iran J Pharm Res 2011;10:25–34.
[41] Karmarkar AB, Gonjari ID, Hosmani AH, et al. Dissolution
rate enhancement of fenofibrate using liquisolid tablet
technique. Lat Am J Pharm 2009;28:219–225.
[42] Hentzschel CM, Sakmann A, Leopold CS. Suitability of
various excipients as carrier and coating materials for
liquisolid compacts. Drug Dev Ind Pharm 2011;37:
1200–1207.
[43] Nokhodchi A, Hentzschel CM, Leopold CS. Drug release from
liquisolid systems: speed it up, slow it down. Expert Opin
Drug Deliv 2011;8:191–205.
[44] Fuji Chemical Industry Co., Ltd. 2011. Fujicalin® – The
unique DCPA. Available from: http://www.fujicalin.com/
product/general_properties.php. [Accessed 28 March 2016].
[45] Fuji Chemical Industry Co., Ltd. 2009. Neusilin ® – The
specialty excipient. Available from: http://www.neusilin
.com/product/general_properties.php. [Accessed 28 March
2016].
[46] Vranikova B, Gajdziok J, Vetchy D. Determination of flowable
liquid retention potential of aluminometasilicate carrier for
liquisolid systems preparation. Pharm Dev Technol
2015;20:839–844.
[47] Hentzschel CM, Alnaief M, Smirnova I, et al. Enhancement of
griseofulvin release from liquisolid compacts. Eur J Pharm
Biopharm 2012;80:130–135.
[48] Speybroeck VM, Mellaerts R, Mols R, et al. Enhanced
absorption of the poorly soluble drug fenofibrate by tuning
its release rate from ordered mesoporous silica. Eur J Pharm
Sci 2010;41:623–630.
[49] Chen B, Quan G, Wang Z, et al. Hollow mesoporous silicas as
a drug solution delivery system for insoluble drugs. Powder
Technol 2013;240:48–53.
[50] Gavali SM, Pacharane SS, Sankpal SV, et al. Liquisolid
compact: a new technique for enhancement of drug
dissolution. Int J Res Pharm Chem 2011;1:705–713.
[51] Yadav VB, Yadav AV. Improvement of solubility and
dissolution of indomethacin by liquisolid and compaction
granulation technique. J Pharm Sci Res 2009;1:44–51.
[52] Adibkia K, Shokri J, Barzegar-Jalali M, et al. Effect of solvent
type on retardation properties of diltiazem HCl form
liquisolid tablets. Colloids Surf B Biointerfaces 2014;113:10–
14.
122 a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 1 1 5 – 1 2 3
[53] Chellaa N, Shastria N, Tadikondab RR. Use of the liquisolid
compact technique for improvement of the dissolution rate
of valsartan. Acta Pharm Sin B 2012;2:502–508.
[54] Vittal GV, Deveswaran R, Bharath S, et al. Formulation
and characterization of ketoprofen liquisolid compacts
by Box-Behnken design. Int J Pharm Investig 2012;2:
150–156.
[55] Bonthagarala B, Sai PDL, Venkata SK, et al. Enhancement of
dissolution rate of clofibrate (BCS Class – II drug) by using
liquisolid compact technology. Int J Biomed Adv & Res
2015;6:288–298.
[56] Pezzini BR, Beringhs AO, Ferraz HG, et al. Liquisolid
technology applied to pellets: evaluation of the feasibility
and dissolution performance using felodipine as a model
drug. Chem Eng Res Des 2016;doi:10.1016/
j.cherd.2016.01.037.
[57] Khan A, Iqbal Z, Shah Y, et al. Enhancement of dissolution
rate of class II drugs (hydrochlorothiazide); a comparative
study of the two novel approaches; solid dispersion
and liquid-solid techniques. Saudi Pharm J 2015;23:
650–657.
[58] Khaled KA, Asiri YA, El-Sayed YM. In vivo evaluation of
hydrochlorothiazide liquisolid tablets in beagle dogs. Int J
Pharm 2001;222:1–6.
[59] Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, et al. The
effect of type and concentration of vehicles on the
dissolution rate of a poorly soluble drug (indomethacin)
from liquisolid compacts. J Pharm Sci 2005;8:18–25.
[60] Yadav VB, Yadav AV. Liquisolid granulation technique for
tablet manufacturing: an overview. J Pharm Res 2009;2:670–
674.
[61] Lu M, Xing HN, Yang TZ, et al. Dissolution enhancement of
tadalafil by liquisolid technique. Pharm Dev Technol
2016;doi:10.1080/10837450.2016.1189563. Accepted.
[62] Elkordy AA, Essa EA, Dhuppad S, et al. Liquisolid technique
to enhance and to sustain griseofulvin dissolution: effect of
choice of non-volatile liquid vehicles. Int J Pharm
2012;434:122–132.
[63] Gonjari ID, Karmarkar AB, Hosmani AH. Evaluation of in vitro
dissolution profile comparison methods of sustained release
tramadol hydrochloride liquisolid compact formulations
with marketed sustained release tablets. Dig J Nanomater
Bios 2009;4:651–661.
[64] Khanfar M, Salem MS, Kaddour F, et al. Preparation of
sustained-release dosage form of Venlafaxine HCl using
liquisolid technique. Pharm Dev Technol 2014;19:103–115.
[65] Ramenskaia GV, Shokhin IE, Savchenko AI, et al. The
dissolution test in biorelevant media as a prognostic tool for
modeling of drug behavior in vivo. Biomed Khim
2011;57:482–489.
[66] Tonnensen HH. Formulation and stability testing of
photolabile drugs. Int J Pharm 2001;225:1–14.
123a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 1 1 5 – 1 2 3
